Photodynamic therapy (
PDT) can produce a large amount of
reactive oxygen species (ROS) in the radiation field to kill
tumor cells. However, the sustainable anti-
tumor efficacy of
PDT is limited due to the hypoxic microenvironment of
tumor. In this study, classic
PDT agent
indocyanine green (ICG) and
hypoxia-activated chemotherapeutic drug
tirapazamine (TPZ) were loaded on mesoporous
polydopamine (PDA) to construct PDA@ICG-TPZ nanoparticles (PIT). Then, PIT was camouflaged with cyclic
arginine-
glycine-
aspartate (cRGD) modified
tumor cell membranes to obtain the engineered membrane-coated nanoreactor (cRGD-mPIT). The nanoreactor cRGD-mPIT could achieve the dual-targeting ability via
tumor cell membrane mediated homologous targeting and cRGD mediated active targeting. With the enhanced
tumor-targeting and penetrating delivery system, PIT could efficiently accumulate in hypoxic
tumor cells and the loaded drugs were quickly released in response to near-infrared (NIR)
laser. The nanoreactor might produce cytotoxic ROS under NIR and further enhance
hypoxia within
tumor to activate TPZ, which efficiently inhibited hypoxic
tumor by synergistic photodynamic-
chemotherapy. Mechanically,
hypoxia-inhibitory factor-1α (HIF-1α) was down-regulated by the synergistic
therapy. Accordingly, the cRGD-mPIT nanoreactor with sustainable and cascade anti-
tumor effects and satisfied biosafety might be a promising strategy in hypoxic
tumor therapy.